Preparing and assessing the physiochemical properties of curcumin niosomes and evaluating their cytotoxicity in 3T3 and MCF-7 cell lines.

Cancer Curcumin Cytotoxicity Drug delivery MTT Niosome

Journal

Avicenna journal of phytomedicine
ISSN: 2228-7930
Titre abrégé: Avicenna J Phytomed
Pays: Iran
ID NLM: 101586220

Informations de publication

Date de publication:
Historique:
received: 19 05 2021
revised: 02 06 2021
accepted: 02 06 2021
entrez: 22 7 2021
pubmed: 23 7 2021
medline: 23 7 2021
Statut: ppublish

Résumé

Application of vesicular drug delivery systems has made major progress in pharmaceutical science and technology. Niosomal drug delivery is potentially efficient to improve the pharmacokinetic and pharmacological properties of many compounds. Curcumin (CUR) has several documented anticancer activities; however, it has a low bioavailability that necessitates the development of efficient delivery systems. Accordingly, different niosomal preparations were prepared and evaluated in the present study to find a suitable delivery system. Span and Tween 20, 40, 60, and 80 were employed with various concentrations of cholesterol for studying the ability to form curcumin-loaded niosomes. Multiple characterization techniques including visual evaluation, particle size analysis, stability, encapsulation efficiency (EE), and release profile were studied. Cytotoxicity of curcumin niosomes on MCF-7 and 3T3 cell lines was determined using MTT assay. Visual and particle size analysis indicated the formation of seven niosomal formulations in the micron size range, while the formulation consisted of Tween 40/cholesterol (50/50 M%) with 0.05% w/v CUR had an average diameter of 475 nm. The latter formulation was selected and it had EE of 78.5%. The CUR release profile showed 18.7% release over a period of 300 min. The MTT results showed that CUR incorporation significantly increased the cytotoxicity of niosomes and the extent of toxicity was higher in MCF-7 cells. In this study, a simple niosomal formulation was developed for CUR loading with favorable physicochemical properties. The presented niosomal curcumin had also considerable effects in cell toxicity studies, which can be suggested for future anticancer studies.

Identifiants

pubmed: 34290972
doi: 10.22038/AJP.2021.18163
pmc: PMC8264222
doi:

Types de publication

Journal Article

Langues

eng

Pagination

417-427

Déclaration de conflit d'intérêts

The authors have declared that there is no conflict of interest.

Références

Mater Sci Eng C Mater Biol Appl. 2019 Jan 1;94:234-246
pubmed: 30423705
Artif Cells Nanomed Biotechnol. 2018 Feb;46(1):118-125
pubmed: 28375753
J Cell Physiol. 2019 May;234(5):5643-5654
pubmed: 30239005
J Biomater Appl. 2021 Feb;35(7):743-753
pubmed: 32807016
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Biochem Biophys Res Commun. 2021 Jan 1;534:980-987
pubmed: 33131770
Curr Med Chem. 2020;27(40):6849-6863
pubmed: 31724497
Soft Matter. 2020 Feb 19;16(7):1779-1791
pubmed: 31970372
Avicenna J Phytomed. 2016 Jul-Aug;6(4):383-98
pubmed: 27516979
World J Gastroenterol. 2016 Mar 7;22(9):2736-48
pubmed: 26973412
Expert Opin Drug Deliv. 2020 Jan;17(1):61-75
pubmed: 31810374
Curr Med Chem. 2020 Nov 11;:
pubmed: 33176632
Microb Pathog. 2020 Jan;138:103806
pubmed: 31629797
Biotechnol Adv. 2014 Nov 1;32(6):1053-64
pubmed: 24793420
Int J Pharm. 2016 Apr 30;503(1-2):115-26
pubmed: 26956159
J Liposome Res. 2021 Jun;31(2):189-194
pubmed: 32292087
Crit Rev Food Sci Nutr. 2020;60(6):887-939
pubmed: 30632782
Mol Neurobiol. 2020 Aug;57(8):3391-3411
pubmed: 32430842
Drug Discov Today. 2017 Oct;22(10):1582-1592
pubmed: 28711364
Polymers (Basel). 2021 Mar 04;13(5):
pubmed: 33806659
Int J Pharm. 2013 Sep 15;454(1):302-9
pubmed: 23830940
Curr Pharm Des. 2013;19(11):1994-2010
pubmed: 23116309

Auteurs

Narges Ashraf Ganjooei (N)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Mandana Ohadi (M)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Seyyed Mohammad Amin Mostafavi (SMA)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Behzad Behnam (B)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Herbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Abbas Pardakhty (A)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Classifications MeSH